WO2014005815A2

WO2014005815A2 - Active ingredient combinations of magnolia bark extract and anise fruit extract and the cosmetic and/or dermatological use thereof

Info

Publication number: WO2014005815A2
Application number: PCT/EP2013/062234
Authority: WO
Inventors: Corinna ILSEMANN; Sarah Hiddemann; Nadeshda Kurz; Joanna Ruhs; Ursula Holtzmann; Marc Winnefeld; Torsten Schläger
Original assignee: Beiersdorf Ag
Priority date: 2012-07-06
Filing date: 2013-06-13
Publication date: 2014-01-09
Also published as: EP2869899A2; WO2014005815A3; DE102012211797A1

Abstract

The invention relates to an active ingredient combination of magnolia bark extract and anise fruit extract, cosmetic and/or dermatological preparations containing said active ingredient combinations and to the use thereof for the cosmetic and/or dermatological treatment and/or prophylaxis of cellulite and/or the signs of skin aging.

Description

description

Combination of extracts of magnolia bark extract and aniseed extract and their cosmetic and / or dermatological use

The present invention relates to cosmetic or dermatological preparations containing active ingredients for the care and protection of the skin, in particular the sensitive skin as well as especially in the foreground standing of intrinsic and / or extrinsic factors aged or aging skin and the use of such agents and combinations such active ingredients in the field of cosmetic and dermatological skin care.

Under cosmetics, one can summarize all measures that make changes to the skin and hair for aesthetic reasons or to cleanse the body. Cosmetics, then, means to care for, improve and beautify the outer body in order to please the fellow human being as well as oneself in a visible, tangible and smelly way.

If this function is disturbed, it may lead to increased absorption of toxic or allergenic substances or the infestation of microorganisms and as a result to toxic or allergic skin reactions.

The aim of skin care is also to compensate for the daily loss of fat and water loss of the skin. This is especially important when the natural regeneration capacity is insufficient. In addition, skin care products to protect against environmental influences, especially from the sun and wind, and delay the aging of the skin.

The chronological skin aging is caused eg by endogenous, genetically determined factors. In the epidermis and dermis, aging causes, for example, the following structural damage and dysfunctions, which may also fall under the term "senile xerosis": a) dryness, roughness and formation of dryness wrinkles,

b) itching and

c) Reduced fatty acid regurgitation (e.g., after washing).

Exogenous factors such as UV light and chemical noxae can be cumulatively effective and e.g. accelerate or supplement endogenous aging processes. In epidermis and dermis, exogenous factors occur, e.g. on the following structural damage and dysfunction in the skin that go beyond the extent and quality of the damage caused by chronological aging: d) visible vascular dilations (telangiectasias, cuperosis);

e) slackness, loss of volume and formation of wrinkles;

f) local hyper, hypo and false pigmentation (e.g., age spots) and

g) increased susceptibility to mechanical stress (e.g., cracking).

The present invention relates in particular to products for the care of naturally aged skin, as well as the phenomena listed under a), e) and g).

Products for the care of relaxed, especially aged, skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or derivatives thereof) or vitamin A and / or its derivatives. Their effect on the structural damage, however, is limited in scope. In addition, there are significant difficulties in product development in stabilizing the active ingredients sufficiently against oxidative degradation. In addition, the use of vitamin A acid-containing products often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.

Often, a concomitant phenomenon of obesity and / or the so-called cellullite often associated with it is associated with the sagging skin.

The body awareness of consumers has increased significantly in recent years. In addition to cleaning and nurturing applications, measures are increasingly taken to improve the body silhouette. Cellulite - a widespread phenomenon - occupies a central position. The visible picture of cellulite is based on an increase in fat deposits in the subcutis (subcutaneous fatty tissue), a weakening of connective tissue and a reduction in the flow conditions in the blood and lymphatic channels. The cause is thus a partial plant-related weakening of the connective tissue with simultaneous occurrence of enlarged fat cell chambers as a result of obesity, unbalanced Diet, lack of exercise. The development of cellulite can also be attributed to an increased permeability of the capillary walls, which allows the penetration of water into the connective tissue.

In addition, there may be a local lack of testosterone on the affected areas of the skin. Anyway, cellulite is a phenomenon that is almost never seen in men.

The object of the present invention was therefore to find ways that avoid the disadvantages of the prior art. In particular, it was an object of the present invention to provide preparations which can bring about an advantageous tightening of softened skin.

Surprisingly, it has been found that active ingredient combinations of magnolia bark extract and aniseed extract and the use of combinations of extracts of magnolia bark extract and aniseed extract for tightening and / or firming the skin, especially in cosmetic or dermatological preparations, remedies the disadvantages of the prior art.

The use of active compound combinations according to the invention or cosmetic or dermatological preparations with an effective content of such active substance combinations z. B. in the form of the examples below - leads in a surprising manner to a significant improvement in the appearance of the skin.

The use of preparations according to the invention also stimulates collagen expression and lipid synthesis and thus positively influences the skin volume.

It was surprising that by applying inventive drug combinations or cosmetic or dermatological preparations with an effective content of such drug combinations, the wrinkle depth and wrinkle number of intrinsically or extrinsically aged skin is reduced and thus, the appearance of aging skin is improved.

It was also surprising that the elasticity of the skin, and therefore cellulite or the appearance of the so-called "orange peel" is improved by applying inventive drug combinations or cosmetic or dermatological preparations with an effective content of such drug combinations. Magnolia (Magnolia) is a genus of flowering plants in the magnolia family (Magnoliaceae). This contains about 230 species that come from East Asia and America. According to the invention, the magnolia seed extract can in principle be taken from all species of the genus Magnolia, although Magnolia grandiflora, and in particular Magnolia officinalis, are preferred.

Magnolia bark is used in traditional Chinese medicine (TCM) mainly for "stagnation of qi" (low energy), emotional stress, inflammation, inner restlessness and anxiety.

The preparation of the extract used is carried out with the aid of supercritical C0 ₂ or ethanol or an ethanol / water mixture.

Magnolol is characterized by the following structure:

Honokiol is characterized by the following structure:

The cosmetic or dermatological preparations according to the invention may be composed as usual and used for the treatment, care and cleansing of the skin and / or the hair and as a make-up product in decorative cosmetics. They preferably contain 0.001% by weight to 10% by weight, preferably 0.05% by weight to 5% by weight, in particular 0.1-1.0% by weight, based on the total weight of the preparations, on magnolia seed extract. It is particularly advantageous according to the invention, an aqueous fruit extract of anise (INCI: Pimpinella anis fruit extract), which is rich in inorganic minerals such as sodium and magnesium ions, especially potassium ions and 0.36% with butylene glycol and parabens 0, 14% is conserved and obtainable by enzymatic hydrolysis in water of solubilized aniseed fruit, wherein the ratio of raw material to extract is about 1: 2 and is available under the trade name Bioxilift® from SILAB, (Brive Cedex, France) ,

Aniseed extract (Bioxylift®, SILAB) is an aqueous fruit extract from anise.

The extract has an amber-like color and has a characteristic anise smell. It is rich in inorganic minerals such as sodium and magnesium ions, but especially in potassium ions.

The specific composition is:

Dry matter: 40 - 60 g / l

Mineral ash: 1 1 - 18 g / l

Total protein: 12 - 20 g / l

pH: 4.5 - 5.5

The extract is unpreserved or preserved and storable. Its preparation is described in International Patent Application WO 02/102347.

Cosmetic or dermatological preparations according to the invention preferably contain from 0.001 to 30% by weight, preferably from 0.1 to 15% by weight, particularly preferably from 0.5 to 7% by weight, based in each case on the total weight of the preparation of aniseed fruit extract ,

Advantageously, weight ratios of magnolia bark extract and aniseed extract are selected from the ranges 1: 20 to 1: 2, preferably from 1: 15 to 1: 4, more preferably from 1:10 to 1: 6.

According to the invention, preparations containing the active compound combinations according to the invention can be used with customary antioxidants.

The antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocaninic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg anserine), carotenoids, carotenes (eg α-carotene, β-carotene, lycopene) and their derivatives, lipoic acid and derivatives thereof (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, Palmitoyl, oleyl, γ-linoleyl, cholesterol and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (eg buthionine sulfoximines , Homocysteinsulfoximin, Buthioninsulfone, penta-, hexa-, heptathionine sulfoximine) in very low tolerated dosages (eg pmol to μηιοΙ / kg), also (metal) chelators (eg α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids ( eg Citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (eg γ-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, alaninediacetic acid, flavonoids, polyphenols , Catechins, vitamin C and derivatives (eg ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (eg vitamin E acetate), as well as benzoic acid coniferyl benzoate, rutinic acid and its derivatives, ferulic acid and its derivatives, butylhydroxytoluene, butylated hydroxyanisole, Nordi Hydroguaiakharzsäure, Nordihydroguajaretsäure, Trihydroxybutyrophenon, uric acid and its derivatives, mannose and their derivatives, zinc and its derivatives (eg ZnO, ZnS0 ₄ ) selenium and its derivatives (eg selenium methionine), stilbenes and their derivatives (eg stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and the like) d lipids) of these active substances.

The amount of antioxidants (one or more compounds) in the preparations is preferably from 0.001 to 30% by weight, particularly preferably from 0.05 to 20% by weight, in particular from 1 to 10% by weight, based on the total weight of the preparation ,

Particularly advantageous embodiments of the present invention consist in active ingredient combinations of magnolia bark extract, an aniseed extract and hyaluronic acid, and the use of combinations of magnolia bark extract, aniseed extract and hyaluronic acid for firming and / or strengthening the skin, especially in cosmetic or dermatological preparations.

Hyaluronic acid is a polysaccharide derivative characterized by the following structural element:

Hyaluronic acid is a glycosaminoglycan found in the connective tissue, vitreous humor, umbilical cord and synovial fluid of the joints. Hyaluronic acid is particularly abundant in early embryonic stages and contributes to cell migration by shielding the cells expressing their surface cells from each other, thus allowing their free mobility. Hyaluronic acid is involved in wound healing

Hyaluronic acid is a high molecular weight compound with molecular weights between 40,000 and several million. For the purposes of the present invention, it is advantageous if the hyaluronic acid used has an average molar mass maximum between 40 kDa and 60 kDa and / or 1000 kDa and 2200 kDa. It is equally advantageous according to the invention if the hyaluronic acid is present in protonated form, as a salt, as a partially protonated salt, dissociated in solution or partially dissociated.

According to the invention, the concentration of hyaluronic acid, based on the total weight of the preparation, is advantageously from 0.001 to 10% by weight, preferably from 0.05 to 5% and very particularly preferably from 0.01 to 2% by weight, based in each case on the total weight of the preparation.

Particularly preferred according to the invention are weight ratios

a) Magnolia bark extract

b) hyaluronic acid and

c) aniseed fruit extract such as a: b: c, where a, b and c independently of one another can represent rational numbers from 1 to 50, preferably from 1 to 30.

Particularly preferred for hyaluronic acid having an average molar mass maximum between 1000 kDa and 2200 kDa is a weight ratio of about 5: 1: 30 to 3: 1 to 26. For hyaluronic acid having an average molecular weight maximum between 40 kDa and 60 kDa, a weight ratio of about 8: 1: 45 to 3: 1: 26 is preferred.

The prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of the active ingredient used according to the invention is carried out in the usual manner, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations having an effective content of active ingredient used according to the invention is applied to the affected skin areas.

Emulsions according to the invention for the purposes of the present invention, e.g. in the form of a cream, a lotion, a cosmetic milk are advantageous and contain e.g. Fats, oils, waxes and / or other fatty substances, as well as water and one or more emulsifiers, as they are commonly used for such a type of formulation.

It is also possible and advantageous in the context of the present invention to incorporate the active ingredient used according to the invention into aqueous systems or surfactant preparations for cleaning the skin and hair.

Of course, it is known to those skilled in the art that sophisticated cosmetic compositions are usually not conceivable without the customary auxiliaries and additives. These include, for example, bodying agents, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, light stabilizers, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytic substances, etc.

Mutatis mutandis, corresponding requirements apply to the formulation of medical preparations.

Medicinal topical compositions according to the present invention usually contain one or more drugs in effective concentration. For the sake of simplicity, reference is made to the clear distinction between cosmetic and medical use and corresponding products to the statutory provisions of the Federal Republic of Germany (for example, Cosmetics Regulation, Food and Medicines Act).

It is also advantageous to use the active ingredient according to the invention as an additive to give preparations which already contain other active substances for other purposes.

The cosmetic and / or dermatological formulations according to the invention may be composed as usual and used for the treatment of the skin and / or the hair in the sense of a dermatological treatment or a treatment in the sense of nourishing cosmetics. But they can also be used in make-up products in decorative cosmetics or in the cosmetic and dermatological cleaning products.

If the cosmetic or dermatological preparation is a solution or lotion, the solvents used can be: water or aqueous solutions, furthermore oils, such as triglycerides of capric or caprylic acid, but preferably castor oil, fats, waxes and other natural and synthetic fatty substances, preferably Esters of fatty acids with low C-number alcohols, eg with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids of low C number or with fatty acids, but also alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether,

Propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.

In particular, mixtures of the abovementioned solvents are used, as may be an advantageous further constituent of alcohol in the case of alcoholic solvents.

Cosmetic and dermatological preparations according to the invention, also e.g. to protect the skin from UV rays may be in various forms, such as e.g. Usually used for this type of preparations. So they can e.g. a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water (W / O / W), oil-in-water-in-oil (O / W / O), a gel, a hydrodispersion, a lamellar phase, a liquid isotropic solution phase, a micellar phase, a solid or dispersed one or more times hexagonal phase, a solid or dispersed single or multi-cubic phase, a lyotropic phase, a crystalline phase, a solid stick or even an aerosol.

The active compounds according to the invention can also be used with particular advantage in microemulsions, for example as described in German Offenlegungsschrift DE-195 9 079. The oil phase of the preparations according to the invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms. Such ester oils can then be advantageously selected from the group

Isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, eg Jojoba oil.

Furthermore, the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, namely the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12 to 18 carbon atoms. For example, the fatty acid triglycerides can be advantageously selected from the group of synthetic, semi-synthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.

Any mixtures of such oil and wax components are also advantageous to use in the context of the present invention.

The oil phase is advantageously selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, _Ci2-i5-alkyl benzoate, caprylic-capric acid triglyceride, dicaprylyl ether.

Particularly advantageous are mixtures of _Ci2-i5-alkyl benzoate and 2-ethylhexyl isostearate, mixtures of Ci2-i5-alkyl benzoate and isotridecyl isononanoate and mixtures of C12-15- benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.

Of the hydrocarbons, paraffin oil, squalane and squalene are to be used advantageously in the context of the present invention. Advantageously, the oil phase may further comprise a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other Olphasenkomponenten except the silicone oil or silicone oils.

Advantageously, cyclomethicone (octamethylcyclotetrasiloxane) is used as the silicone oil to be used according to the invention. However, other silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).

Also particularly advantageous are mixtures of cyclomethicone and isotridecyl isononanoate, cyclomethicone and 2-ethylhexyl isostearate.

Advantageously, the content of the oil phase is between 1 and 50 wt .-%, based on the total weight of the preparations, preferably 2.5 to 30 wt .-%, particularly preferably 5 to 15 wt .-%.

For use, the cosmetic and / or dermatological formulations according to the invention are applied to the skin in a sufficient amount in the manner customary for cosmetics and dermatological agents.

Proof of efficacy:

Induction of adipogenesis

Subcutaneous human preadipocytes isolated from the femoral region of different donors (LOT L041806, L080608) were commercially purchased from Zen-Bio Inc. (Research Triangle Park, NC).

The cells were cultured in basal medium (10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U / mL penicillin and 100 μg / mL streptomycin, Cambrex, Verviers, Belgium) for 7 days at 37 ° C and 5%. C0 ₂ in the cell incubator. The cell culture medium was renewed on the first and fourth day after sowing.

Subsequently, the cells were passaged in 96 well plates (1x10 ⁴ cells per well). Twenty-four hours after passage into the 96 well plates, cells were treated with differentiation medium without indomethacin (basal medium containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U / mL penicillin, and 100 μg / mL streptomycin, 10 μg / mL Insulin, 1 μM dexamethasone and 500 μM isobutylmethylxanthine; Cambrex, Verviers, Belgium) are incubated with the following active ingredients and drug combinations: magnolia bark extract (10 μΜ), aniseed extract ("Bioxilift") (0.5%), magnolia bark extract (10 μΜ) + aniseed extract ( "Bioxilift") (0.5%).

The "negative control" used was a cell population cultured without addition of active ingredient, and rosiglitazone (2.25 μΜ) was used as the "positive control". Staining of triglyceride accumulation during differentiation was performed on day 7 post-induction

AdipoRed reagent (Cambrex, Verviers, Belgium) according to the manufacturer's instructions. The fluorescence (ex 485 nm, em 572 nm) was finally determined with an Infinite M200 plate reader (Tecan, Crailsheim, Germany).

The following examples are intended to illustrate the embodiments of the present inventions.

Example Example Example Example Example

INCI

1 2 3 4 5

1, 2-hexanediol 0.50 0.50 0.70 0.60

Acrylate / C 10-30 Alkyl Acrylate Crosspolymer 0.10 0.20 0.15 0.10

Bis-Ethylhexyloxyphenolmethoxyphenyltriazin 1, 00 1, 50 2.00 0.50

Butylene glycol dicaprylate / dicaprate 2.50 1.00

Butylmethoxydibenzoylmethane 4.00 2.00 3.00

Butyrospermum Parkii (Shea Butter) 6.00 7.00 1, 00 3.00

C12-15 alkyl benzoate 2.00 1, 00 1, 00

Caprylic / capric triglyceride 3.00 4.00

Carbomer 0.30 0.10 0.40 0.20 0.10

Cetearyl alcohol 1, 00 2.50 2.00 3.00

Cetyl alcohol 1, 00 1, 00 1, 50

Cetyl palmitate 2.50 2.00 4.00

Dibutyl adipate 3.00 3.00

Diethylaminohydroxybenzoylhexylbenzoate 3.50

Dimethicone 0.50 0.80 0.30

Ethylhexylglycerol 0.25 0.30 0.50

Ethylhexyl salicylate 4.50 5.00 3.00

Ethylhexyltriazine 2.50

Glycerin 10.00 9.00 8.00 12.00 8.00

Glyceryl stearate 2.50 2.00 2.80

Glyceryl stearate citrate 1, 50 2.50 hydrogenated coconut glycerides 1, 00 2.00 2.00 1, 00 3.50

Isopropyl palmitate 2.50

Magnolia Officinalis Bark Extract 0.50 0.50 0.40 0.80 0.70

Methylparaben 0.20

Methylpropanediol 2.00 1, 50 2.00 1, 00

Sodium hyaluronate, average Molmassenmaxi¬

0.15 0.10 0.20 μm between 1000 kDa and 2200 kDa

Sodium hyaluronate, average Molmassenmaxi¬

0.10 0.15 mum between 40 kDa and 60 kDa

Octyldodecanol 2.00 2.00 3.00

Panthenol 2.00 5.00 Perfume qsqsqsqsqs

Phenoxyethanol 0.60 0.60 0.80 0.40 0.80

Phenylbenzimidazole sulfonic acid 2.00 1.00 0.50

Polymethylsilsesquioxane 2.00 1.00 1.00

Sodium stearoyl glutamate + sodium chloride 0.20 0.50 0.10

Stearyl alcohol 1.00 2.00

Synthetic Beeswax 1.00 2.00 2.00 3.00

Water ad 100% ad 100% ad 100% ad 100% ad 100%

Water + Pimpinella Anisum (aniseed extract) 4.00 3.50 2.80 5.00 5.50

Water + sodium hydroxide 1.10 0.90 0.40 0.70 0.10

Water + Trisodium EDTA 1.20 1.00 1.10 0.80 1.00

Claims

claims:

1. Active substance combinations of magnolia bark extract and aniseed extract.

2. active compound combinations according to claim 1, characterized in that the magnolia bark extract is obtained from the bark of Magnolia officinalis.

3. active compound combinations according to claim 1, characterized in that the magnolia bark extract is obtained by means of supercritical C0 ₂ or ethanol or an ethanol / water mixture

4. Active substance combinations according to one of the preceding claims, characterized in that the aniseed extract is an aqueous fruit extract of anise (INCI: Pimpinella anis fruit extract), which is rich in inorganic minerals such as sodium and magnesium ions, especially potassium ions and is 0.36% with butylene glycol and 0.14% parabens, and is obtainable by enzymatic hydrolysis in water of solubilized aniseed fruit, wherein the ratio of raw material to extract is about 1: 2.

5. Active ingredient combinations according to one of the preceding claims, in which weight ratios of magnolia bark extract and aniseed extract from those from the ranges 1: 20 to 1: 2, preferably from 1: 15 to 1: 4, particularly preferably from 1:10 to 1: 6, to get voted

6. Cosmetic or dermatological preparations containing active compound combinations according to one of the preceding claims.

7. Preparations according to claim 8, containing 0.001 wt .-% to 10 wt .-%, preferably 0.05 wt .-% to 5 wt .-%, in particular 0, 1 - 2.0 wt .-%, based on the total weight of the preparations, of magnolia bark extract.

8. Preparations according to claim 6 or 7 containing 0.001 to 10% by weight, preferably from 0.05 to 5% by weight and very particularly preferably from 0.01 to 2% by weight of aniseed extract, in each case based on the total weight of the preparation.

9. Use of active compound combinations according to any one of claims 1-5 or cosmetic or dermatological preparations according to any one of claims 6 - 8 for the cosmetic and / or dermatological treatment and / or prophylaxis of cellulite.

10. Use of active compound combinations according to any one of claims 1-5 or cosmetic or dermatological preparations according to any one of claims 6 - 8 for the cosmetic and / or dermatological treatment and / or prophylaxis of the appearance of the skin of the old.